Why it may help Gastritis: Calms gastric inflammation
Gastritis
Get updatesOverview
Gastritis is an inflammation of the stomach lining, which can be acute (sudden onset) or chronic (developing gradually over time).
When to seek urgent medical care
- Severe abdominal pain
- Vomiting blood or black, tarry stools
- Shortness of breath
- Dizziness or lightheadedness
- Unexplained weight loss
- Persistent vomiting
- Difficulty swallowing
Common symptoms
- Abdominal pain (gnawing or burning)
- Nausea
- Vomiting
- Feeling of fullness after eating
- Loss of appetite
- Indigestion
Possible contributors
- H. pylori infection
- NSAID use
- Excessive alcohol consumption
- Stress
- Autoimmune reactions
- Bile reflux
- Viral infections
- Crohn's disease
Labs to discuss with your clinician
- H. pylori test (breath, stool, or biopsy)
- Complete blood count (CBC)
- Endoscopy with biopsy
- Stool antigen test
- Iron studies (if anemia suspected)
All Remedies
Ranked by community outcomes, then evidence grade, Health Voice mentions, and recency.
Remedies
Why it may help Gastritis: Supports gastric repair
Why it may help Gastritis: Repairs gastric mucosa
- Typical dose
- 75 mg/day
- Mechanism
- May help protect and repair the stomach lining and suppress H. pylori.
- Notes
- Often taken twice daily.
- Evidence
- moderate
Why it may help Gastritis: Soothes gastric lining
- Typical dose
- 50-150 ml/day
- Mechanism
- May have anti-inflammatory and soothing properties for the digestive tract.
- Notes
- Ensure it is decolorized to remove laxative compounds.
- Evidence
- limited
Why it may help Gastritis: DGL licorice may help Gastritis by stimulating the production of protective mucus and prostaglandins in the stomach, which can aid in healing and reduce inflammation.
- Typical dose
- 300-400 mg, 2-3 times daily before meals
- Mechanism
- May stimulate the production of protective mucus in the stomach lining.
- Notes
- Deglycyrrhizinated form avoids side effects of glycyrrhizin.
- Evidence
- moderate
Why it may help Gastritis: L-Glutamine may help Gastritis by supporting the integrity of the gastric mucosal barrier, which can reduce inflammation and promote healing of the stomach lining.
- Typical dose
- 5-10 grams/day
- Mechanism
- An amino acid that supports the integrity of the gut lining.
- Notes
- Can be taken in divided doses.
- Evidence
- limited
Carminative seed for bloating, gas, and digestion.
Why it may help Gastritis: Zinc carnosine may help Gastritis by promoting the healing of gastric ulcers and strengthening the stomach's mucosal barrier, thereby protecting against further damage.
- Typical dose
- 75 mg/day
- Mechanism
- May help protect and repair the stomach lining and suppress H. pylori.
- Notes
- Often taken twice daily.
- Evidence
- moderate
Emerging Research
Why it may help Gastritis: Marshmallow root may help Gastritis by forming a protective mucilaginous layer over the inflamed stomach lining, potentially soothing irritation and aiding in tissue repair.
Why it may help Gastritis: Slippery elm may help Gastritis by forming a protective mucilaginous layer over the inflamed stomach lining, potentially soothing irritation and promoting healing.
Aerobic and resistance exercise have RCT-grade evidence for depression, comparable to SSRIs in mild-moderate cases.
Why it may help Gastritis: Manuka honey reduces gastritis severity
Why it may help Gastritis: Calms gastric tract
Why it may help Gastritis: Anti-inflammatory and gastric protective
Why it may help Gastritis: Reduces gastric inflammation
- Typical dose
- Various strains and CFUs
- Mechanism
- May help balance gut flora, especially beneficial when H. pylori is present or after antibiotic use.
- Notes
- Specific strains like Lactobacillus and Bifidobacterium may be beneficial.
- Evidence
- moderate
Why it may help Gastritis: Aloe vera juice may help Gastritis by reducing inflammation and promoting the healing of the gastric mucosa, potentially alleviating pain and discomfort.
- Typical dose
- 50-150 ml/day
- Mechanism
- May have anti-inflammatory and soothing properties for the digestive tract.
- Notes
- Ensure it is decolorized to remove laxative compounds.
- Evidence
- limited
Community outcomes
What people report for Gastritis
Self-reported by community members · not medical advice.
What people report for this condition
Self-reported community outcomes. Not medical advice. Requires at least three reports per remedy to surface.
Community outcome data is still being collected for this ailment.
Be the first to share your experience →People Like Me insights
As more members share outcomes, RemedyAtlas will show which remedies helped people with similar conditions, symptoms, goals, and lab patterns.
Community discussion
Structured experience reports from people managing this condition. Not medical advice.
You can share without an account — we'll send a one-time code to verify your email. Or sign in.
Loading posts…
Community Discussions
What people say about Gastritis
Lifestyle foundations
- Identify and avoid triggers
- Stress management
- Adequate sleep
- Regular physical activity
- Avoid smoking
- Limit alcohol intake
Dietary recommendations
- Anti-inflammatory diet
- Avoid spicy foods
- Limit acidic foods
- Avoid caffeine
- Eat smaller, more frequent meals
- Increase fiber intake
- Avoid processed foods
- Stay hydrated
Lifestyle interventions
- Mindful eating practices (chew food thoroughly)
- 7-9 hours sleep with consistent bedtime
- Daily 10-min diaphragmatic breathing
- Regular moderate exercise (e.g., walking 30 mins/day)
- Avoid eating 2-3 hours before bedtime
- Practice stress reduction techniques (e.g., meditation, yoga)
Evidence at a glance
Moderate Evidence
Traditional Use
International evidence & guidelines
How global health authorities view Gastritis.
The Mayo Clinic highlights that gastritis can be caused by H. pylori infection, NSAID use, and excessive alcohol, and recommends avoiding irritants and managing stress. The National Center for Complementary and Integrative Health (NCCIH) suggests that some herbal remedies, like ginger, are used for digestive issues, but often notes that more rigorous research is needed to confirm efficacy for specific conditions like gastritis. While some traditional remedies are widely used, major health bodies generally emphasize conventional medical diagnosis and treatment for gastritis, especially for H. pylori infection or severe symptoms. Dietary modifications and stress reduction are commonly supported as complementary approaches.
Evidence ecosystem
Indexed studies for Gastritis, grouped by source type and quality.
Filter by source type
Meta-Analyses(12)
Pooled analyses across multiple human trials.
Meta-analysis of H. pylori and the gut microbiome interactions and clinical outcomes.
Wu X, Zhu H, Hu Y, Zhang L, Huang L · Frontiers in cellular and infection microbiology · 2025
Helicobacter pylori is a globally prevalent gastric pathogen associated with chronic gastritis, peptic ulcers, and gastric cancer. Its interaction with the gut microbiome (GM), a dynamic microbial community within the gastrointestinal tract, plays a critical role in modulating host immune responses and disease progression. This study aimed to investigate the complex interactions between H. pylori infection and the GM and to evaluate how microbiome alterations relate to clinical outcomes such as gastritis, ulcers, and gastric cancer. A meta-analysis was conducted using publicly available 16S rRNA and shotgun metagenomic datasets. Microbiome composition differences were assessed using differential abundance analysis, alpha- and beta-diversity metrics, and principal component analysis (PCA). Random forest models were employed to predict the clinical outcomes based on microbiome and clinical data. Hyperparameter tuning and cross-validation were applied to ensure model robustness. The ana
Meta-AnalysisPubMedVery High QualityChiang CH, Jaroenlapnopparat A, Colak SC, Yu CC, Xanthavanij N, Wang TH · Gastroenterology · 2025 · n=395
Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are widely used for glycemic control or weight management in patients with type 2 diabetes mellitus or overweight/obesity. However, there are concerns regarding their association with serious gastrointestinal adverse events, although findings have been inconsistent. We systematically searched 5 databases for placebo-controlled randomized controlled trials assessing GLP-1RAs in patients with type 2 diabetes mellitus, overweight/obesity, or metabolic dysfunction-associated steatohepatitis/metabolic dysfunction-associated steatotic liver disease. We included trials that reported cholecystitis, cholelithiasis, cholangitis, cholestasis, pancreatitis, gastroesophageal reflux disease (GERD), gastritis, esophagitis, gastrointestinal ischemia, gastrointestinal hemorrhage, intestinal obstruction, paralytic ileus, gastrointestinal ulceration, gastrointestinal perforation, or gastroparesis. Meta-analyses were performed using a random-effects mo
Meta-AnalysisPubMedVery High QualityPrevalence of Autoimmune Gastritis Worldwide: A Systematic Review and Meta-Analysis.
Li M, Huang Y, Liang X, Lu H · Helicobacter · 2025
Autoimmune gastritis (AIG) is a chronic immune-mediated disease characterized by the presence of anti-parietal cell antibody and progressive corpus-predominant atrophy. The global prevalence of AIG and its associated factors remain poorly understood. This study aimed to systematically estimate the prevalence of AIG worldwide and identify demographic and diagnostic factors influencing its variability. In this systematic review and meta-analysis, we searched Medline, Scopus, and Embase from database inception until December 7, 2024. Prevalence was pooled using a random-effects model, and potential sources of heterogeneity were explored by subgroup analysis and meta-regression analysis. A total of 47 studies involving 15,817 individuals were included. The global prevalence of AIG was estimated at 3.85% (95% CI: 2.94-5.04, I2 = 99.3%). Notable geographical variation was observed, with a prevalence of 4.94% in Europe (95% CI: 3.66-6.63), 2.23% in Asia (95% CI: 1.19-4.14), 2.
Meta-AnalysisPubMedVery High Quality
Systematic Reviews(6)
Structured reviews of the full body of evidence (incl. Cochrane).
Lei H, Sun W, Liu X, Wang C · Journal of gastrointestinal cancer · 2024
Pembrolizumab is associated with the development of gastritis, but its clinical features have not been characterized. To explore the clinical features of pembrolizumab induced gastritis and provide reference for the prevention and treatment of gastritis. Case reports and case series related to pembrolizumab induced gastritis were retrospectively analyzed by searching the database from inception to September 30, 2023. Thirty-nine patients with gastritis entered the study with a median age of 63 years (range 34, 81). The median time to gastritis was 11.1 months (range 0.3, 60) and 7 cycles (range 1, 27) after administration. Epigastric pain (24 cases, 61.5%), nausea (17 cases, 43.6%), and vomiting (16 cases, 41.0%) were the most frequently complained symptoms. Esophagogastroduodenoscopy mainly showed erythematous (16 cases, 41.0%), hemorrhage (14 cases, 35.9%) and erosions (11 cases, 28.2%). Gastric mucosal biopsy shows chronic active gastritis with lymphocytic infiltration.
Systematic ReviewPubMedVery High QualityA Systematic Review of Symptoms of Pernicious Anemia.
Seage CH, Bennett A, Ward N, Semedo L, Plattel CHM, Suijker KIM · Food and nutrition bulletin · 2024 · n=103
Pernicious anemia (PA) is a type of macrocytic anemia caused by autoimmune gastritis. To facilitate timely diagnosis and treatment of PA there is a pressing need for improved understanding among Healthcare providers of the condition's symptoms and diagnostic criteria. This systematic review aims to extend existing clinical knowledge on the presentation of PA by determining which symptoms and clinical complications are reported in published adult case studies. Relevant studies were identified through electronic searches of PsycINFO, Embase, and MEDLINE, via OvidSP. During data extraction symptoms were categorized according to the International Classification of Diseases and were grouped based on frequency. Symptoms were documented for 103 adults with a diagnosis of PA; the most frequent symptoms were fatigue (55%), loss of sensation in limbs (32%), excessive weight loss (27%), and a sore tongue (23%). This review highlights the diverse symptomology of adults who are diagnosed with P
Systematic ReviewPubMedVery High QualityTadesse TY, Zeleke MM, Dagnew SB, Addis GT · Journal of experimental pharmacology · 2023
The Urticaceae family contains 54 genera and more than 2000 species that can be found in tropical, subtropical, and temperate climates all over the world. This family includes the largest genus in the world, Urtica, which is also known as stinging nettle. Stinging hairs are present on the lower surface of the leaves and beneath the stems of Urtica simensis, also known as the stinging nettle, herbal nettle that is dioecious, upright, and unbranched. For the treatment of conditions like gastritis, heart disease, diabetes, gonorrhea, and malaria, people employ various portions of Urtica simensis in a variety of ways in traditional medicine. The Urtica simensis leaves are rich in variety of active secondary phytochemical constituents including terpenoids, saponins, tannins, flavonoids, steroids, alkaloids, polyphenols, sterols, oxalate, and ascorbic acid (vitamin C). According to different reports, it possesses a variety of pharmacological properties, including antioxidant, antiproliferati
Systematic ReviewPubMedVery High Quality
Randomized Human Trials(9)
Controlled human studies with random assignment.
T(H)2 cell compensatory effect following benralizumab treatment for eosinophilic gastritis.
Ben-Baruch Morgenstern N, Rochman Y, Caldwell JM, Collins MH, Mukkada VA, Putnam PE · The Journal of allergy and clinical immunology · 2024
Eosinophil accumulation is a main feature of eosinophilic gastritis (EoG) and is associated with its histologic diagnosis and pathology. However, a recent clinical trial has demonstrated that EoG endoscopic, noneosinophil histologic, and clinical features remain persistent despite complete eosinophil depletion. Our aim was to examine gastric T-cell composition and associated cytokine levels of patients with EoG following benralizumab-induced eosinophil depletion versus following administration of placebo. A cohort of subjects with EoG from a subset of subjects who participated in a recent phase 2 benralizumab trial was treated for 12 weeks with administration of 3 doses of benralizumab (anti-IL-5 receptor α antibody [n = 5]) or placebo (n = 4). Single-cell suspensions obtained by gastric biopsy were stimulated with phorbol 12,13-dibutyrate and ionomycin in the presence of brefeldin A and monensin. Harvested cells were fixed, stained, and analyzed by flow cytometr
Randomized TrialPubMedHigh QualityYang YY, Li KM, Xu GF, Wang CD, Xiong H, Wang XZ · World journal of gastroenterology · 2024
Although chronic erosive gastritis (CEG) is common, its clinical characteristics have not been fully elucidated. The lack of consensus regarding its treatment has resulted in varied treatment regimens. To explore the clinical characteristics, treatment patterns, and short-term outcomes in CEG patients in China. We recruited patients with chronic non-atrophic or mild-to-moderate atrophic gastritis with erosion based on endoscopy and pathology. Patients and treating physicians completed a questionnaire regarding history, endoscopic findings, and treatment plans as well as a follow-up questionnaire to investigate changes in symptoms after 4 wk of treatment. Three thousand five hundred sixty-three patients from 42 centers across 24 cities in China were included. Epigastric pain (68.0%), abdominal distension (62.6%), and postprandial fullness (47.5%) were the most common presenting symptoms. Gastritis was classified as chronic non-atrophic in 69.9% of patients. Among those with erosive l
Randomized TrialPubMedHigh QualityZou TH, Gao QY, Liu S, Li YQ, Meng XJ, Zhang GX · Journal of digestive diseases · 2024 · n=166
To investigate the clinical potential and safety of Moluodan to reverse gastric precancerous lesions. Patients aged 18-70 years diagnosed with moderate-to-severe atrophy and/or moderate-to-severe intestinal metaplasia, with or without low-grade dysplasia, and negative for Helicobacter pylori were recruited in this randomized, double-blind, parallel-controlled trial. The primary outcome was the improvement of global histological diagnosis at 1-year follow-up endoscopy using the operative link for gastritis assessment, the operative link for gastric intestinal metaplasia assessment, and the disappearance rate of dysplasia. Between November 3, 2017 and January 27, 2021, 166 subjects were randomly assigned to the Moluodan group, 168 to the folic acid group, 84 to the combination group, and 84 to the high-dose Moluodan group. The improvement in global histological diagnosis was achieved in 60 (39.5%) subjects receiving Moluodan, 59 (37.8%) receiving folic acid, 26 (32.1%) receiving
Randomized TrialPubMedHigh Quality
Observational Studies(34)
Cohort, case-control, and cross-sectional human studies.
A long-standing undiagnosed case of vitamin B12 deficiency: a case report.
Mesgarankarimi A, Rezapour M, Tabrizi N · Journal of medical case reports · 2025
Pernicious anemia, an autoimmune disease, presents with gradual, nonspecific symptoms, often leading to delayed diagnosis owing to its overlap with other conditions and variability in laboratory findings, such as neurological symptoms without anemia or macrocytosis. This case describes a 40-year-old Iranian woman with a decade-long history of nonspecific symptoms, including fatigue, widespread musculoskeletal pain, paresthesia, cognitive disturbances, and optic neuritis; misattributed to conditions such as fibromyalgia, hypothyroidism, and autoimmune diseases. Despite annual monitoring for normocytic anemia, her critically low vitamin B12 levels (< 150 pg/mL) and a diagnosis of pernicious anemia were identified only after persistent symptoms prompted further evaluation, revealing atrophic gastritis as the underlying cause. Neurologic improvement with parenteral B12 therapy, alongside management of fibromyalgia, emphasizes the importance of considering vitamin B12 defici
Observational StudyPubMedLow QualityAutoimmune Gastritis and Helicobacter pylori Infection: Molecular Mechanisms of Relationship.
Bordin DS, Livzan MA, Mozgovoi SI, Gaus OV · International journal of molecular sciences · 2025
Helicobacter pylori (H. pylori) infection and autoimmune inflammation of the gastric mucosa are recognized as the leading etiological factors of chronic atrophic gastritis. The mechanisms of atrophy formation and progression with the risk of gastric cancer development are heterogeneous, which requires a deeper study of the molecular mechanisms of relationship, peculiarities of the course of autoimmune gastritis both in combination with H. pylori and after eradication, as well as without H. pylori infection (naïve AIG). This article presents the specific molecular and cellular patterns in the formation of these related conditions.
Observational StudyPubMedLow QualityMa XY, Hao Y, Xie YH, Cao Q, Sun DF, Wang JL · Journal of gastroenterology and hepatology · 2025 · n=479
Here, we ascertained the clinical characteristics of Chinese patients with autoimmune gastritis (AIG) and determined the correlation of dietary and lifestyle factors with AIG occurrence and development to establish a noninvasive predictive model for AIG. In this case-control study, we enrolled 479 patients from seven independent centers nationwide in China; of them, 279 had AIG, 112 had chronic atrophic gastritis mostly in the antrum, and 88 had chronic nonatrophic gastritis. Their clinical and lifestyle data were systematically collected and analyzed. Finally, a multivariate logistic regression disease prediction model was then established and validated. Most of the 279 patients with AIG were middle-aged, older, and female. In the predictive model of AIG, the larger amount of cooking oil used per meal and comorbid autoimmune thyroid disease was considered risk factors, and a diet rich in vitamin B12 was considered a protective factor. We plotted a receiver operating characteristic (
Observational StudyPubMedModerate Quality
Animal Studies(1)
Preclinical animal research — not a substitute for human evidence.
Chu X, Biao Y, Li H, Chen J, Yin J, Gao X · Lipids in health and disease · 2025 · n=23
Lipid metabolism may be linked to chronic gastritis, but its causal role remains unclear. While current research emphasizes inflammation, mucosal changes, immune regulation, genetics, and the gut microbiota, the contribution of lipid metabolism is understudied. This study aims to evaluate the impact of serum lipids and the mechanistic roles of lipid-lowering drug targets in chronic gastritis. We conducted a cross-sectional study using data from real world. Multivariable logistic regression was performed to assess the association between serum lipid profiles and gastritis. Mendelian randomization (MR) analyses based on genome-wide association study (GWAS) datasets were performed to detect the causal relationship of serum lipids, plasma lipid species, and lipid-lowering drug targets. Experimental validation was conducted using high-fat diet (HFD)-fed mice and chemically induced CAG rat models. Four thousand sixty one person, including 1,023 patients with chronic atrophic gastritis (CAG
Animal StudyPubMedLow Quality
Government Health Sources(1)
Public-health agencies: NCCIH, NIH, CDC, NHS.
NHS
The NHS offers details on gastritis, covering symptoms, causes, and advice on managing the condition, targeted at public understanding.
Government SourceNHSHigh Quality
Clinical Trial Registries(109)
Registered ongoing or completed trials (ClinicalTrials.gov).
n=330 · NCT02246439 · COMPLETED · COMPLETED
Randomized, Placebo-Controlled, Phase 3 Trial of RHB-102 (BEKINDA) (Ondansetron 24 mg Bimodal Release Tablets) for Acute Gastroenteritis. The study will evaluate the safety and efficacy of RHB-102 (BEKINDA) in treating Acute Gastroenteritis, by comparing it to placebo.
Clinical TrialClinicalTrials.govModerate Qualityn=1300 · NCT04840056 · RECRUITING · RECRUITING
The primary objectives of this study are: * To identify clinical or histological factors associated with gastric cancer development in patients with IM and AG * To establish a machine learning algorithm for prediction of future gastric cancer risks and individual risk stratification in patient with IM and AG
Clinical TrialClinicalTrials.govModerate Qualityn=671 · NCT06269380 · COMPLETED · COMPLETED
Esophagogastroduodenoscopy (EGD) is commonly performed in patients presenting with abdominal pain and dyspeptic symptoms, serving as a valuable diagnostic and therapeutic tool. While various methods are available for biopsy sampling when mucosal pathology is observed during EGD, the practice of obtaining biopsies from endoscopically normal mucosa remains controversial. Although there is literature suggesting that routine biopsies from the antrum and duodenum for surveillance purposes increase costs, pathological findings can sometimes be detected in areas that appear normal on mucosal examination, leading to potential changes in treatment approach if biopsies are obtained. In this study, a retrospective evaluation of the prevalence of various pathologies detected in biopsies obtained from endoscopically normal mucosa in patients who underwent EGD was reported as normal.
Clinical TrialClinicalTrials.govModerate Quality
Evidence Summaries(4)
Curated cross-source summaries (TRIP Database and similar).
Cochrane
This search link provides access to systematic reviews of interventions for gastritis from the Cochrane Library, offering high-quality evidence synthesis.
Evidence SummaryCochraneHigh QualityTRIP Database
The TRIP Database offers a search platform to find evidence-based information on gastritis, including guidelines, systematic reviews, and primary research.
Evidence SummaryTRIP DatabaseHigh QualityCochrane Library search for "Gastritis"
Cochrane
The Cochrane Library is a collection of databases that contain different types of high-quality, independent evidence to inform healthcare decision-making, including systematic reviews relevant to gastritis.
Evidence SummaryCochraneHigh Quality
Working alongside conventional care
Conventional treatment for gastritis typically involves antacids, H2 blockers, or proton pump inhibitors (PPIs) to reduce stomach acid. If H. pylori is present, antibiotics are prescribed. Lifestyle and dietary changes are also commonly recommended.
Related conditions
Latest News
Latest news on Gastritis
Health Videos
Health videos on Gastritis
This information is for educational purposes only and should not replace professional medical advice. Always consult a healthcare provider for diagnosis and treatment of gastritis.
Found something that helped your gastritis?
Help others see what actually works.
Found something that helped your gastritis?
Real-world results help others choose what's worth trying.